Literature DB >> 8125837

Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.

E W van Etten1, C van den Heuvel-de Groot, I A Bakker-Woudenberg.   

Abstract

The in-vitro activities of amphotericin B-desoxycholate (AmB-DOC), liposomal amphotericin B (L-AmB) and fluconazole were determined against a single strain of Candida albicans. In addition, the efficacies of these agents in the treatment of systematic candidosis in both immunocompetent and leucopenic mice were compared. The minimum inhibitory concentrations (MICs) and minimum fungicidal concentrations (MFCs) of AmB-DOC and L-AmB were similar, but on the basis of time-kill studies, the fungicidal activity of L-AmB was significantly less than that of AmB-DOC. In immunocompetent mice, the dosage of AmB-DOC was limited by toxicity, resulting in a maximum tolerated dosage (MTD) of 0.4 mg/kg/day during treatment for 5 days; L-AMB was less toxic, the MTD being 7 mg/kg/day following a treatment period of the same duration. Both AmB-DOC and L-AmB led to significant reductions in the numbers of C. albicans in the kidneys of these mice and prevented relapse of infection after completion of treatment. Fluconazole in dosages of 0.4 and 64 mg/kg/day resulted in initial reductions in the numbers of cfu but failed to prevent relapse. In leucopenic mice, treatment for 5 days with AmB-DOC in a dosage of 0.3 mg/kg/day resulted in survival of the animals and a significant reduction in the numbers of cfu in the liver, spleen and lungs. However, there was no reduction in the number of cfu in the kidneys and this led to relapse of infection once therapy was terminated. Fluconazole in a dosage of 64 mg/kg/day produced effects which were similar to those of AmB-DOC; prolonged treatment with fluconazole for 18 days did not improve the efficacy of this agent. Only treatment with high-dosage (7 mg/kg/day) L-AmB was effective in significantly reducing the numbers of cfu of C. albicans in the kidneys and other organs of leucopenic mice, as well as preventing relapse, even in severely infected animals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8125837     DOI: 10.1093/jac/32.5.723

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.

Authors:  Donna M MacCallum; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.

Authors:  Jon A Olson; Jill P Adler-Moore; Julie Schwartz; Gerard M Jensen; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice.

Authors:  A J van Deventer; W H Goessens; A van Belkum; E W van Etten; H J van Vliet; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

Review 4.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

5.  Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

Authors:  V Heinemann; D Bosse; U Jehn; B Kähny; K Wachholz; A Debus; P Scholz; H J Kolb; W Wilmanns
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 6.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 7.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

Review 8.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

9.  Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice.

Authors:  N C Karyotakis; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

10.  Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases.

Authors:  Ying Hong; Peter J Shaw; Christa E Nath; Satya P Yadav; Katherine R Stephen; John W Earl; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.